Press Release Archive

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE): ($ in millions, except per share amounts) Fourth-Quarter Full-Year 2008 2007

(BUSINESS WIRE)--Pfizer Inc said today it has received a complete response letter from the U.S. Food and Drug Administration (FDA) asking for additional information on the company’s application for lasofoxifene. The investigational compound is currently under review for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. Pfizer is reviewing the letter and will work with FDA to determine the

(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a “Notice of Allowance” accepting the company’s application to correct the technical defect in the ‘995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor. The company noted that certain formalities must be completed before the reissue patent will be granted. The reissued patent will have

(BUSINESS WIRE)--Pfizer Inc today announced that Bradley E. Lerman will join the company as Senior Vice President, Litigation. Mr. Lerman, who will be responsible for leading the company’s litigation efforts, will report to Senior Vice President and General Counsel Amy W. Schulman. Since 1998, Mr. Lerman has served as a litigation partner at Winston & Strawn LLP in Chicago, where he concentrated his practice in white-

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Wednesday, January 28, 2009. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2008 Performance Report, to be issued that morning To view and listen to the webcast and view the Performance Report, visit

(BUSINESS WIRE)--Pfizer Inc (Pfizer) and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A (Sigma-Tau), a privately owned Italian pharmaceutical company, announced today that they have entered into a license and supply agreement under which, following applicable regulatory submissions and approvals, the companies will market Eurartesim®, a novel fixed dose artemisinin-based combination therapy (ACT), in Africa.

(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has granted SELZENTRY™ (maraviroc) full (traditional) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals. SELZENTRY was originally granted accelerated conditional approval in August 2007 based on 24-week data from pivotal Phase 3 studies. SELZENTRY now becomes the latest fully approved treatment for HIV

(BUSINESS WIRE)--Pfizer today announced the launch of a new research unit known as Pfizer Regenerative Medicine. This independent research unit will build on recent scientific progress in understanding the biology of stem cells and the opportunity that provides, to discover and develop a new generation of regenerative medicines for major medical needs. The new unit will announce several significant scientific collaborations in the coming weeks

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Jeff Kindler, Chairman and CEO, at the 2008 Credit Suisse Healthcare Conference on Thursday, November 13 at 11:00 a.m. Mountain Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “2008 Credit Suisse Healthcare Conference” link in the Investor